IVD Medical (1931.HK HKSE) down 14.09% pre-market 05 Feb 2026: key trading signals

1931.HK stock plunged 14.09% pre-market to HK$1.28 on 05 Feb 2026 after heavy selling and a spike in volume. Trading hit 10,624,000 shares versus an average of 3,982,751, giving a relative volume of 2.67. The sell-off pushed the intraday low to HK$1.27 and left the share price far below its 50-day average of HK$3.32 and 200-day average of HK$5.03. Investors will watch earnings due 13 Mar 2026 and whether the company’s PE 10.67 and cash conversion issues attract short interest in Hong Kong healthcare names.

1931.HK stock pre-market movers and volume context

Trading activity led the move: volume 10,624,000 today is 2.67x the normal flow, signalling institutional or headline-driven selling. The share opened at HK$1.50 then dropped to a day low of HK$1.27, with a day high of HK$1.53. One clear fact: high turnover on a steep decline increases short-term volatility and raises the chance of additional near-term downside in Hong Kong (HKSE) session.

1931.HK stock fundamentals and valuation snapshot

IVD Medical Holding Limited (1931.HK) trades at PE 10.67 with EPS HK$0.12 and market capitalisation around HK$2.08B. Price-to-book is 0.53, and price-to-sales is 0.60, below the Healthcare sector average PE of 29.06, which compresses valuation risk but also reflects slower growth. The company reports high inventory days (about 478.32 days) and a current ratio of 1.79, pointing to working capital pressure that likely factors into the sell-off.

1931.HK stock technicals and short-term support

Technicals show oversold conditions: RSI 24.99 and ADX 47.03 indicating a strong downward trend. Key technical levels: immediate support is HK$1.27, resistance at HK$1.50 then the 50-day average at HK$3.32. Bollinger lower band sits at HK$1.53, so price is trading near the band bottom. Traders should note MACD histogram and momentum readings signalling persistent selling pressure.

1931.HK stock Meyka grade and model forecast

Meyka AI rates 1931.HK with a score out of 100: 65.13 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target HK$1.87 (implied upside 46.09%) and a yearly target HK$7.49 (implied upside 484.77%) vs current HK$1.28. Forecasts are model-based projections and not guarantees. See company site IVD Medical and filings on HKEX for primary documents. Internal data and realtime signals available at Meyka: 1931.HK.

1931.HK stock catalysts, risks and sector view

Near-term catalysts include the earnings release on 13 Mar 2026 and any updates on distribution contracts or self-branded reagent uptake in Mainland China. Key risks: high inventory days, stretched cash conversion cycle (453.13 days), rising debt (debt-to-equity 0.48) and a weak operating cash flow trend. The Healthcare sector in Hong Kong trades richer on average; IVD’s lower multiples may reflect execution risk rather than pure value.

1931.HK stock trading strategy and price targets

Short-term traders may set a stop near HK$1.20 with a first profit target at HK$1.50 and a secondary target at HK$3.32 (50-day MA). Longer-term investors should wait for improved cash conversion metrics or a clear revenue lift from self-branded products before increasing exposure. Analysts’ technical scenario: a close above HK$1.60 on volume could signal consolidation.

Final Thoughts

The sell-off in 1931.HK stock — down 14.09% pre-market to HK$1.28 on 05 Feb 2026 — reflects a mix of technical pressure and fundamental concerns. Volume surged to 10,624,000, suggesting forced or large-block selling. Valuation metrics (PE 10.67, PB 0.53) indicate the share is inexpensive versus Healthcare peers, but operational metrics such as days inventory 478.32 and a lengthy cash conversion cycle are red flags. Meyka AI’s model highlights divergent scenarios: a near-term recovery to HK$1.87 (≈46.09% upside) or a longer re-rating toward HK$7.49 if growth and cash flow materially improve (≈484.77% upside). Use tight risk controls: traders should watch the HKSE session for follow-through, monitor the earnings update on 13 Mar 2026, and prefer size discipline given the stock’s volatility. Remember, Meyka AI provides data-driven analysis but this is not investment advice; always confirm with primary filings and your advisor.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.